Physician profile
Sumeet Mathur
NPI 1609864115
$17,145.59
in general payments reported to CMS, 2019-2025
24 companies · $4,304 in 2025
The $4,304 reported for 2025 was more than what 95% of Plastic Surgery Within The Head & Neck providers received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,025 · 2020: $183 · 2021: $473 · 2022: $4,138 · 2023: $4,314 · 2024: $1,708 · 2025: $4,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,761 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,616 · Consulting Fee: $2,034 · Travel and Lodging: $859 · Education: $56.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,760.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,616.00 |
| Consulting Fee | $2,034.00 |
| Travel and Lodging | $858.61 |
| Education | $56.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $6,439.94 | 2019-2025 | |
| Stryker Corporation | $2,469.90 | 2019-2025 | Xpress Ent Dilation System, Xpress Loprofile, Scopis Ent |
| Acelrx Pharmaceuticals, INC. | $2,281.38 | 2021-2022 | |
| Aerin Medical INC. | $1,523.20 | 2019-2025 | |
| Medical Device Business Services, INC. | $1,291.81 | 2019 | |
| Acclarent, INC | $866.96 | 2019-2024 | Acclarent Aera, Relieva Spinplus, Acclarent Navwire |
| Regeneron Healthcare Solutions, INC. | $554.21 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $430.13 | 2022-2024 | Nucala |
| Ars Pharmaceuticals Operations, INC. | $331.69 | 2025 | Neffy |
| Csl Behring | $247.34 | 2025 | Haegarda, Andembry |
| Kaleo, INC. | $108.06 | 2020-2022 | |
| Neurent Medical Limited | $97.94 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Integra Lifesciences Corporation | $95.99 | 2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Intersect Ent, INC. | $92.40 | 2019-2021 | |
| Optinose US, INC. | $65.89 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $56.95 | 2023 | |
| Medtronic USA, INC. | $33.09 | 2020 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Inspire Medical Systems, INC. | $27.09 | 2023 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $24.90 | 2025 | Tezspire |
| Medtronic, INC. | $23.56 | 2022 | |
| Xoran Technologies LLC | $23.44 | 2023 | Minicat |
| Novartis Pharmaceuticals Corporation | $19.08 | 2019 | |
| Alk-Abello, INC | $13.40 | 2023 | Standardized Mite D. Farinae, Timothy, Standardized, Alternaria Tenuis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumeet Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.